DENVER, Colo., Feb 04, 2025 (247marketnews.com)- 24/7 Market News, a trusted source for real-time financial news and market analysis, highlights today’s most significant stock movements and breaking developments shaping the financial landscape.
Quantum BioPharma (NASDAQ:QNTM) announced the completion of a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, unbuzzd, on alcohol intoxication and metabolism. The results showed that unbuzzd significantly accelerated the reduction of blood alcohol concentration (BAC), reducing it over 40% faster within 30 minutes compared to a placebo.
Trial participants reported improvements in alertness and reduced perceived impairment. furthermore, and lessened hangover symptoms, including a 67% reduction in headache severity.
Dr. Andrzej Chruscinski, Quantum’s VP of Clinical and Scientific Affairs, stated, “We are thrilled to see such significant and meaningful outcomes in this clinical study. This study confirms the exceptional overall performance of unbuzzd to help reduce the acute effects of alcohol intoxication. We are also pleased to see that there were no product-related side effects or safety concerns in this clinical study.”
Cumberland Pharmaceuticals (NASDAQ:CPIX) announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it’s the first successful Phase 2 study specifically targeting the cardiac complications of their condition.
Larry W. Markham, MD, the FIGHT DMD trial’s Principal Investigator, stated, “These results represent a significant milestone in DMD cardiomyopathy. We are seeing evidence that there is an opportunity to potentially alter the course of heart disease in DMD patients. The improvement in cardiac function observed with ifetroban, particularly in the high-dose group, offers hope for these patients and their families.”
Siyata Mobile (NASDAQ:SYTA) previously announced that it plans to relocate its current 4G and next generation 5G PTT handset manufacturing operations from China to the United States. in 2025.
Marc Seelenfreund, Siyata’s CEO, commented, “We began working on a manufacturing relocation plan earlier this year and are proud to announce today that we expect to begin manufacturing operations in the U.S. in the first quarter of 2025. This is an important strategic move that we believe will open up additional sales opportunities globally, particularly in the U.S., and help us to further scale our business. Users of our devices, especially governmental agencies and first responders, value America manufactured products, but just as important, this move will enable us to shorten delivery lead times and operate within a stronger logistics infrastructure. We are very excited to be making this move and believe it is an important milestone for Siyata.”
SIyata, which strengthened its operating fundamentals in 2024 and developed a strong product offering pipeline, also plans on holding a highly anticipated shareholder event is preparing to “make an announcement that is poised to redefine its trajectory.”
“Siyata is entering a transformative phase, and this development marks the culmination of months of strategic negotiations and execution. All shareholders are strongly encouraged to attend to appreciate the significant implications for 2025,” stated Seelenfreund.
Captivision (NASDAQ:CAPT), Grab Holdings (NASDAQ:GRAB), and BigBearai (NYSE:BBAI) are trading higher on larger than average volume.
Additional 24/7 Market News Siyata disclosure
The post Hot Stocks on the Move appeared first on 24/7 MarketNews.